Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 336-343

  Leamon, Christopher P ^a   Reddy, Joseph A ^a   Klein, Patrick J ^a   Vlahov, Iontcho R ^a   Dorton, Ryan ^a   Bloomfield, Alicia ^a   Nelson, Melissa ^a   Westrick, Elaine ^a   Parker, Nikki ^a   Bruna, Kristen ^a   Vetzel, Marilynn ^a   Gehrke, Mark ^a   Nicoson, Jeffrey S ^a   Messmann, Richard A ^a   LoRusso, Patricia M ^b   Sausville, Edward A ^c  

^a Endocyte Inc   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EC 0489; EC 145; UNCLASSIFIED DRUG; VINCA ALKALOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONSTIPATION; CYTOTOXICITY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER CLEARANCE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; VINCA ALKALOIDS;

EID: 78751537219     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175109     Document Type: Article

References (19)

1. Cao Q, Li ZB, Chen K, Wu Z, He L, Neamati N, and Chen X (2008) Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging 35:1489-1498.
2. Gilbert CW, McGowan EB, Seery GB, Black KS, and Pegram MD (2003) Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker. J Exp Ther Oncol 3:27-35.
3. Henry MD, Wen S, Silva MD, Chandra S, Milton M, and Worland PJ (2004) A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64:7995-8001.
4. Leamon CP (2008) Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9:1277-1286.
5. Leamon CP and Jackman AL (2008) Exploitation of the folate receptor in the management of cancer and inflammatory disease, in Vitamins and Hormones (Litwack G ed) pp 203-233, Academic Press, San Diego.
6. Leamon CP, Reddy JA, Dorton R, Bloomfield A, Emsweller K, Parker N, and Westrick E (2008a) Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. J Pharmacol Exp Ther 327:918-925.
7. Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, and Vlahov I (2008b) Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res 68:9839-9844.
8. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Dawson A, Dorton R, Vetzel M, Santhapuram HK, and Wang Y (2007a) Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 4:659-667.
9. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, and Vetzel M (2007b) Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 121:1585-1592.
10. Leamon CP, You F, Santhapuram HK, Fan M, and Vlahov IR (2009) Properties influencing the relative binding affinity of pteroate derivatives and drug conjugates thereof to the folate receptor. Pharm Res 26:1315-1323.
11. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, and Green MA (1996) Tumorselective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 37:1003-1008.
12. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, and Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293.
13. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, and Leamon CP (2007a) Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67:4434-4442.
14. Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, and Leamon CP (2007b) Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 67:6376-6382. (Pubitemid 47037521)
15. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, and Leamon CP (2006) Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 58:229-236.
16. Sausville E, LoRusso P, Quinn M, Forman K, Leamon C, Morganstern D, Bever S, and Messmann R (2007) A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. J Clin Oncol 25 (18 Suppl):2577.
17. Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, et al. (2004) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl- N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 64:4629-4636.
18. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, and Leamon CP (2006) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16:5093-5096.
19. Vlahov IR, Santhapuram HK, You F, Wang Y, Kleindl PJ, Hahn SJ, Vaughn JF, Reno DS, and Leamon CP (2010) Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates. J Org Chem 75:3685-3691.